BR112022012255A2 - Formulações injetáveis de ação prolongada de sais de pamoato de cetamina - Google Patents

Formulações injetáveis de ação prolongada de sais de pamoato de cetamina

Info

Publication number
BR112022012255A2
BR112022012255A2 BR112022012255A BR112022012255A BR112022012255A2 BR 112022012255 A2 BR112022012255 A2 BR 112022012255A2 BR 112022012255 A BR112022012255 A BR 112022012255A BR 112022012255 A BR112022012255 A BR 112022012255A BR 112022012255 A2 BR112022012255 A2 BR 112022012255A2
Authority
BR
Brazil
Prior art keywords
long
injectable formulations
ketamine pamoate
acting injectable
pamoate salts
Prior art date
Application number
BR112022012255A
Other languages
English (en)
Inventor
Lin Tong-Ho
Wen Yung-Shun
Chen Chia-Hsien
Liu Ying-Ting
Hou Rui-Zhi
Wu Zhi-Rong
Original Assignee
Alar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alar Pharmaceuticals Inc filed Critical Alar Pharmaceuticals Inc
Publication of BR112022012255A2 publication Critical patent/BR112022012255A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

FORMULAÇÕES INJETÁVEIS DE AÇÃO PROLONGADA DE SAIS DE PAMOATO DE CETAMINA. São providas composições farmacêuticas de liberação sustentada, incluindo um sal de pamoato de cetamina e um carreador farmaceuticamente aceitável do mesmo. As composições incluem suspensão aquosa, solução e sistema de entrega de matriz, que podem proporcionar uma liberação sustentada para anestesia, analgesia ou tratamento de doenças do sistema nervoso central e anti-inflamatórias.
BR112022012255A 2019-12-20 2020-12-18 Formulações injetáveis de ação prolongada de sais de pamoato de cetamina BR112022012255A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962951061P 2019-12-20 2019-12-20
PCT/CN2020/137496 WO2021121366A1 (en) 2019-12-20 2020-12-18 Long-acting injectable formulations of ketamine pamoate salts

Publications (1)

Publication Number Publication Date
BR112022012255A2 true BR112022012255A2 (pt) 2022-08-30

Family

ID=76478186

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012255A BR112022012255A2 (pt) 2019-12-20 2020-12-18 Formulações injetáveis de ação prolongada de sais de pamoato de cetamina

Country Status (15)

Country Link
US (1) US20240099994A1 (pt)
EP (1) EP4076410A4 (pt)
JP (1) JP2023505963A (pt)
KR (1) KR20220118427A (pt)
AR (1) AR120816A1 (pt)
AU (1) AU2020410549A1 (pt)
BR (1) BR112022012255A2 (pt)
CA (1) CA3152593A1 (pt)
CL (1) CL2022001636A1 (pt)
CO (1) CO2022003543A2 (pt)
IL (1) IL294089A (pt)
MX (1) MX2022006596A (pt)
PE (1) PE20231942A1 (pt)
TW (1) TW202135782A (pt)
WO (1) WO2021121366A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111936127A (zh) 2018-02-15 2020-11-13 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
MX2020011653A (es) 2018-05-04 2021-02-09 Perception Neuroscience Inc Métodos de tratamiento para el abuso de sustancias.
WO2023178039A1 (en) * 2022-03-14 2023-09-21 Perception Neuroscience, Inc. Pharmaceutical formulations of r-ketamine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2968221T (lt) * 2013-03-15 2019-07-25 Janssen Pharmaceutica Nv S-ketamino hidrochlorido farmacinė kompozicija
RU2021114918A (ru) * 2016-12-26 2021-07-09 Целликс Био Прайвет Лимитед Композиции и способы лечения хронической боли
WO2019073408A1 (en) * 2017-10-10 2019-04-18 Douglas Pharmaceuticals Ltd. PROLONGED RELEASE PHARMACEUTICAL FORMULATION AND TREATMENT METHODS
WO2019172920A1 (en) * 2018-03-09 2019-09-12 Rk Pharmaceuticals, Llc Injectable composition for controlled-release of active ingredient to manage postoperative pain or neuropathic back pain
WO2019186357A1 (en) * 2018-03-26 2019-10-03 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
KR20210116517A (ko) * 2019-01-11 2021-09-27 에일러 파마슈티컬스 아이엔씨. 케타민 파모에이트 및 이의 용도

Also Published As

Publication number Publication date
PE20231942A1 (es) 2023-12-05
CL2022001636A1 (es) 2023-01-27
EP4076410A1 (en) 2022-10-26
US20240099994A1 (en) 2024-03-28
EP4076410A4 (en) 2024-02-07
AR120816A1 (es) 2022-03-23
WO2021121366A1 (en) 2021-06-24
MX2022006596A (es) 2022-07-05
CN114340603A (zh) 2022-04-12
CA3152593A1 (en) 2021-06-24
CO2022003543A2 (es) 2022-04-19
KR20220118427A (ko) 2022-08-25
TW202135782A (zh) 2021-10-01
JP2023505963A (ja) 2023-02-14
AU2020410549A1 (en) 2022-04-14
IL294089A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
BR112022012255A2 (pt) Formulações injetáveis de ação prolongada de sais de pamoato de cetamina
ECSP22047876A (es) Derivados de pirazolilo ?tiles como agentes anticancer?genos
EA201992484A1 (ru) Системы доставки с замедленным высвобождением, содержащие бесследные линкеры
AR109590A2 (es) Régimen posológico para inhibidores de comt
BR112018070602A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
UY29301A1 (es) Derivados amida
BR112018070956A2 (pt) compostos da fórmula, composições farmacêuticas e métodos para distribuir um ácido nucleico para o fígado de um animal e para preparar um composto da fórmula
BR112013030894A2 (pt) moduladores do sistema imune
BR112015015477A2 (pt) derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk
BR112015025766A2 (pt) derivado de nucleosídeo altamente ativo para o tratamento de hcv
UY30686A1 (es) "receptor nicotinico de acetilcolina, subtipo selectivo de amidas de diazabiciloalcanos"
UY28578A1 (es) Derivados de amida
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
CY1118057T1 (el) Φαρμακευτικη συνθεση για στοματικη χορηγηση
BR112022003434A2 (pt) Composição de liberação retardada de niclosamida e uso antiviral da mesma
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
MX2020003993A (es) Derivados de bencimidazol y sus usos.
CU20220024A7 (es) Compuestos aromáticos bicíclicos derivatizados por ácido fenilacético y bencilamina, útiles en el tratamiento de trastornos inmunológicos, enfermedades del sistema nervioso central, neurodegenerativas, renales y cardiovasculares
BR112013024801A2 (pt) formulações de otamixaban com estabilidade aprimorada
ECSP19084722A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
BR112012020377A2 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BR112019000509A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica